209 related articles for article (PubMed ID: 11089243)
21. Topoisomerase poisons: harnessing the dark side of enzyme mechanism.
Froelich-Ammon SJ; Osheroff N
J Biol Chem; 1995 Sep; 270(37):21429-32. PubMed ID: 7665550
[No Abstract] [Full Text] [Related]
22. Topoisomerases, new targets in cancer chemotherapy.
Zijlstra JG; de Jong S; de Vries EG; Mulder NH
Med Oncol Tumor Pharmacother; 1990; 7(1):11-8. PubMed ID: 2160032
[TBL] [Abstract][Full Text] [Related]
23. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
[TBL] [Abstract][Full Text] [Related]
24. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
25. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity.
Patel S; Sprung AU; Keller BA; Heaton VJ; Fisher LM
Mol Pharmacol; 1997 Oct; 52(4):658-66. PubMed ID: 9380029
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES
Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578
[TBL] [Abstract][Full Text] [Related]
27. Cloning of yeast TOP1, the gene encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and DNA topoisomerase II.
Goto T; Wang JC
Proc Natl Acad Sci U S A; 1985 Nov; 82(21):7178-82. PubMed ID: 2997777
[TBL] [Abstract][Full Text] [Related]
28. DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
Nitiss J; Wang JC
Proc Natl Acad Sci U S A; 1988 Oct; 85(20):7501-5. PubMed ID: 2845409
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase II, not topoisomerase I, is the proficient relaxase of nucleosomal DNA.
Salceda J; Fernández X; Roca J
EMBO J; 2006 Jun; 25(11):2575-83. PubMed ID: 16710299
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results.
Cartei G; Trestin A; Colombrino E; Nadai M; Richter SN; Barzon L; Palù G; Palumbo M;
Ann Oncol; 2006 May; 17 Suppl 5():v25-28. PubMed ID: 16807458
[TBL] [Abstract][Full Text] [Related]
31. Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents.
Makhey D; Li D; Zhao B; Sim SP; Li TK; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem; 2003 Apr; 11(8):1809-20. PubMed ID: 12659767
[TBL] [Abstract][Full Text] [Related]
32. Effects of modifying topoisomerase II levels on cellular recovery from radiation damage.
Gaffney DK; Lundquist M; Warters RL; Rosley R
Radiat Res; 2000 Oct; 154(4):461-6. PubMed ID: 11023611
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerases: from a laboratory curiosity to a subject in cancer chemotherapy.
Wang JC
NCI Monogr; 1987; (4):3-6. PubMed ID: 2819727
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
van Hille B; Clerc X; Creighton AM; Hill BT
Br J Cancer; 1999 Nov; 81(5):800-7. PubMed ID: 10555749
[TBL] [Abstract][Full Text] [Related]
36. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
Keller BA; Patel S; Fisher LM
Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):329-39. PubMed ID: 9164874
[TBL] [Abstract][Full Text] [Related]
37. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents.
van Hille B; Hill BT
Cancer Chemother Pharmacol; 1998; 42(5):345-56. PubMed ID: 9771947
[TBL] [Abstract][Full Text] [Related]
38. Antifungal activity of eupolauridine and its action on DNA topoisomerases.
Khan SI; Nimrod AC; Mehrpooya M; Nitiss JL; Walker LA; Clark AM
Antimicrob Agents Chemother; 2002 Jun; 46(6):1785-92. PubMed ID: 12019091
[TBL] [Abstract][Full Text] [Related]
39. Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin.
Bjornsti MA; Knab AM; Benedetti P
Cancer Chemother Pharmacol; 1994; 34 Suppl():S1-5. PubMed ID: 8070016
[TBL] [Abstract][Full Text] [Related]
40. Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Nair JS; Kancherla R; Seiter K; Traganos F; Tse-Dinh YC
Ann N Y Acad Sci; 2000; 922():326-9. PubMed ID: 11193914
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
